Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial

English version České info

Background:
Neuraminidase inhibitors are thought to be efficacious in reducing the time to alleviation of symptoms in outpatients with seasonal influenza. The objective of this study was to compare the short-term virological efficacy of oseltamivir-zanamivir combination versus each monotherapy plus placebo.

Methods and Findings:
We conducted a randomized placebo-controlled trial with 145 general practitioners throughout France during the 2008–2009 seasonal influenza epidemic. Patients, general practitioners, and outcome assessors were all blinded to treatment assignment. Adult outpatients presenting influenza-like illness for less than 36 hours and a positive influenza A rapid test diagnosis were randomized to oseltamivir 75 mg orally twice daily plus zanamivir 10 mg by inhalation twice daily (OZ), oseltamivir plus inhaled placebo (O), or zanamivir plus oral placebo (Z). Treatment efficacy was assessed virologically according to the proportion of patients with nasal influenza reverse transcription (RT)-PCR below 200 copies genome equivalent (cgeq)/µl at day 2 (primary outcome), and clinically to the time to alleviation of symptoms until day 14. Overall 541 patients (of the 900 planned) were included (OZ, n = 192; O, n = 176; Z, n = 173), 49% male, mean age 39 years. In the intention-to-treat analysis conducted in the 447 patients with RT-PCR-confirmed influenza A, 46%, 59%, and 34% in OZ (n = 157), O (n = 141), and Z (n = 149) arms had RT-PCR<200 cgeq/µl (−13.0%, 95% confidence interval [CI] −23.1 to −2.9, p = 0.025; +12.3%, 95% CI 2.39–22.2, p = 0.028 for OZ/O and OZ/Z comparisons). Mean day 0 to day 2 viral load decrease was 2.14, 2.49, and 1.68 log₁₀ cgeq/µl (p = 0.060, p = 0.016 for OZ/O and OZ/Z). Median time to alleviation of symptoms was 4.0, 3.0, and 4.0 days (+1.0, 95% CI 0.0–4.0, p = 0.018; +0.0, 95% CI −3.0 to 3.0, p = 0.960 for OZ/O and OZ/Z). Four severe adverse events were observed. Nausea and/or vomiting tended to be more frequent in the combination arm (OZ, n = 13; O, n = 4; and Z, n = 5 patients, respectively).

Conclusions:
In adults with seasonal influenza A mainly H3N2 virus infection, the oseltamivir-zanamivir combination appeared less effective than oseltamivir monotherapy, and not significantly more effective than zanamivir monotherapy. Despite the theoretical potential for the reduction of the emergence of antiviral resistance, the lower effectiveness of this combination calls for caution in its use in clinical practice.

Trial registration:
www.ClinicalTrials.gov NCT00799760

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial. PLoS Med 7(11): e32767. doi:10.1371/journal.pmed.1000362
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1000362

Souhrn

Trial registration:
www.ClinicalTrials.gov NCT00799760

: Please see later in the article for the Editors' Summary

Zdroje

1. BurchJ

CorbettM

StockC

NicholsonK

ElliotAJ

2009 Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. Lancet Infect Dis 9 537 545

2. HaydenFG

OsterhausAD

TreanorJJ

FlemingDM

AokiFY

1997 Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 337 874 880

3. NicholsonKG

AokiFY

OsterhausAD

TrottierS

CarewiczO

2000 Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355 1845 1850

4. TreanorJJ

HaydenFG

VroomanPS

BarbarashR

BettisR

2000 Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 283 1016 1024

5. JeffersonT

JonesM

DoshiP

Del MarC

2009 Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 339 b5106

6. PuhakkaT

LehtiH

VainionpaaR

JormanainenV

PulkkinenM

2003 Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. Scand J Infect Dis 35 52 58

7. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group 1998 Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 352 1877 1881

8. PolandGA

JacobsonRM

OvsyannikovaIG

2009 Influenza virus resistance to antiviral agents: a plea for rational use. Clin Infect Dis 48 1254 1256

9. WuJT

LeungGM

LipsitchM

CooperBS

RileyS

2009 Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS Med 6 e1000085 doi:10.1371/journal.pmed.1000085

10. SheuTG

DeydeVM

Okomo-AdhiamboM

GartenRJ

XuX

2008 Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52 3284 3292

11. DawoodFS

JainS

FinelliL

ShawMW

LindstromS

2009 Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360 2605 2615

12. WongSC

ChanJK

LeeKC

LoES

TsangDN

2005 Development of a quantitative assay for SARS coronavirus and correlation of GAPDH mRNA with SARS coronavirus in clinical specimens. J Clin Pathol 58 276 280

13. DuchampMB

CasalegnoJS

GilletY

FrobertE

BernardE

2010 Pandemic A(H1N1)2009 influenza virus detection by real time RT-PCR: is viral quantification useful? Clin Microbiol Infect 16 317 321

14. HaydenFG

TreanorJJ

FritzRS

LoboM

BettsRF

1999 Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 282 1240 1246

15. GubarevaLV

KaiserL

HaydenFG

2000 Influenza virus neuraminidase inhibitors. Lancet 355 827 835

16. NguyenJT

HoopesJD

LeMH

SmeeDF

PatickAK

2010 Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 5 e9332 doi:10.1371/journal.pone.0009332

17. RussellRJ

HaireLF

StevensDJ

CollinsPJ

LinYP

2006 The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443 45 49

18. AokiFY

BoivinG

RobertsN

2007 Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 12 603 616

19. GubarevaLV

KaiserL